

Hae-Jin Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6682374/publications.pdf>

Version: 2024-02-01

23
papers

610
citations

687363
13
h-index

642732
23
g-index

24
all docs

24
docs citations

24
times ranked

938
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 Guidelines for the Management of Dyslipidemia in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 78.	3.5	100
2	Visfatin Induces Inflammation and Insulin Resistance via the NF- κ B and STAT3 Signaling Pathways in Hepatocytes. Journal of Diabetes Research, 2019, 2019, 1-11.	2.3	89
3	Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κ B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. Journal of Immunology Research, 2021, 2021, 1-11.	2.2	69
4	Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: <scp>A</scp> nationwide population-based cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1852-1858.	4.4	46
5	Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Cardiovascular Diabetology, 2018, 17, 91.	6.8	41
6	The Association of Adiponectin and Visceral Fat with Insulin Resistance and β -Cell Dysfunction. Journal of Korean Medical Science, 2019, 34, e7.	2.5	38
7	Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus. Circulation: Heart Failure, 2017, 10, .	3.9	36
8	Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study. Journal of Diabetes Research, 2016, 2016, 1-9.	2.3	33
9	Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. Journal of Clinical Medicine, 2019, 8, 28.	2.4	23
10	MicroRNA-132 Negatively Regulates Palmitate-Induced NLRP3 Inflammasome Activation through FOXO3 Down-Regulation in THP-1 Cells. Nutrients, 2017, 9, 1370.	4.1	17
11	Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovascular Diabetology, 2020, 19, 95.	6.8	16
12	Impact of Cadmium Exposure on the Association between Lipopolysaccharide and Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2015, 12, 11396-11409.	2.6	14
13	Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2592-2600.	2.8	14
14	Effect of sarpogrelate, a selective 5-HT 2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes. Atherosclerosis, 2017, 257, 47-54.	0.8	13
15	Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochemical and Biophysical Research Communications, 2022, 588, 154-160.	2.1	12
16	Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Journal of Diabetes Research, 2018, 2018, 1-10.	2.3	10
17	CCL20 induced by visfatin in macrophages via the NF- κ B and MKK3/6-p38 signaling pathways contributes to hepatic stellate cell activation. Molecular Biology Reports, 2020, 47, 4285-4293.	2.3	10
18	Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice. Journal of Hepatology, 2022, 77, 735-747.	3.7	8

#	ARTICLE	IF	CITATIONS
19	Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. <i>Clinical Therapeutics</i> , 2020, 42, 2021-2035.e3.	2.5	6
20	Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway. <i>Biomedicines</i> , 2022, 10, 1032.	3.2	6
21	Acute Glucose Shift Induces the Activation of the NLRP3 Inflammasome in THP-1 Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9952.	4.1	4
22	Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study. <i>Diabetes Care</i> , 2022, 45, 1141-1150.	8.6	3
23	Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 689-700.	4.7	2